Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 02, 2021 16:05 ET | Source: CVRx, Inc.

CVRx, Inc. Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

MINNEAPOLIS, July 02, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally...
June 29, 2021 20:17 ET | Source: CVRx, Inc.

CVRx, Inc. Announces Upsized Pricing of Initial Public Offering

MINNEAPOLIS, June 29, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally...
June 10, 2021 11:19 ET | Source: CVRx, Inc.

CVRx® Announces First Clinical Procedure with a New Ultrasound-Guided Implant Approach, the Latest Advancement in Barostim™ for the Treatment of Heart Failure Symptoms

MINNEAPOLIS, June 10, 2021 (GLOBE NEWSWIRE) -- CVRx®, developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure (HF), announced the completion of the...
March 15, 2021 10:00 ET | Source: CVRx, Inc.

Fierce Medtech Names CVRx as One of its “Fierce 15” Companies

MINNEAPOLIS, March 15, 2021 (GLOBE NEWSWIRE) -- CVRx®, developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure (HF), announces it has been selected...
January 05, 2021 10:55 ET | Source: CVRx, Inc.

CVRx® Appoints New Chief Marketing Officer and Vice President of European Sales and Marketing

MINNEAPOLIS, Jan. 05, 2021 (GLOBE NEWSWIRE) -- CVRx®, developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure (HF), announced that it is expanding...
December 03, 2020 11:54 ET | Source: CVRx, Inc.

CVRx® BAROSTIM Therapy Receives CMS Approval for Transitional Pass-Through Payment Status

MINNEAPOLIS, Dec. 03, 2020 (GLOBE NEWSWIRE) -- CVRx®, developer of the world’s first FDA-approved neuromodulation device to treat the symptoms of heart failure (HF), announced that the Centers for...
November 18, 2020 14:56 ET | Source: CVRx, Inc.

CVRx® Announces New CFO and Acceleration of Barostim Therapy Commercialization Efforts

MINNEAPOLIS, Nov. 18, 2020 (GLOBE NEWSWIRE) -- CVRx, Inc., developer of FDA-approved Barostim Therapy to treat chronic heart failure (HF), announced a CFO transition as part of the company’s...

keyboard_arrow_left Previous Page